Skip to main content
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 2018 Oct 2;128(11):5184. doi: 10.1172/JCI125039

PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy

Dmitriy Zamarin, Jacob M Ricca, Svetlana Sadekova, Anton Oseledchyk, Ying Yu, Wendy M Blumenschein, Jerelyn Wong, Mathieu Gigoux, Taha Merghoub, Jedd D Wolchok
PMCID: PMC6205393  PMID: 30277478

Original citation: J Clin Invest. 2018;128(4):1413–1428. https://doi.org/10.1172/JCI98047

Citation for this corrigendum: J Clin Invest. 2018;128(11):5184. https://doi.org/10.1172/JCI125039

Jedd D. Wolchok’s conflict-of-interest information was incomplete. The omitted statement is below.

JDW has acted as a consultant for Adaptive Biotechnologies, Advaxis, Amgen, Apricity, Array BioPharma, Ascentage Pharma, BeiGene, Bristol-Myers Squibb, Celgene, Chugai Pharmaceutical Co., Elucida Oncology Inc., Eli Lilly and Company, F-Star, Genentech, Imvaq Therapeutics Corp., Kleo Pharmaceuticals, MedImmune, Merck, Neon Therapuetics, Ono Pharmaceutical Co., Polaris Pharma, Polynoma, PsiOxus Therapeutics, PureTech Health, Recepta Biopharma SA, Trieza Therapeutics, Sellas Life Sciences, Serametrix Immune Monitoring, Surface Oncology, and Syndax; has received research support from Bristol-Myers Squibb, MedImmune, Merck, Genentech; and has equity in Potenza Therapeutics (cofounder), Tizona Therapeutics (cofounder), Adaptive Biotechnologies, Elucida Oncology Inc., Imvaq Therapeutics Corp., BeiGene, and TriEnza.

The authors regret the error.

Version 1. 10/02/2018

Electronic publication

Version 2. 11/01/2018

Print issue publication

Footnotes


Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES